Advertisement

Advertisement

Lung Cancer

FDA Approves Therapy for NSCLC With High c-Met Protein Overexpression

On May 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to telisotuzumab vedotin-tllv (Emrelis), a c-Met–directed antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic, nonsquamous, non–small cell lung cancer (NSCLC) with high c-Met ...

Bladder Cancer
Thyroid Cancer
Gastroesophageal Cancer
Neuroendocrine Tumors
Colorectal Cancer
Lung Cancer
Lymphoma
Multiple Myeloma

NCCN Clinical Practice Guidelines in Oncology: 2025 Updates

The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are available for more than 60 tumor types, subtypes, and related topics. During the NCCN’s 30th Annual...

Lung Cancer

Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations

In an interim analysis of a Japanese trial (ACHILLES/TORG1834) reported in the Journal of Clinical Oncology, Miura et al found that afatinib prolonged progression-free survival vs platinum-based chemotherapy in patients who had treatment-naive nonsquamous non–small cell lung cancer (NSCLC) with...

Colorectal Cancer
Lung Cancer
Solid Tumors
Symptom Management

In Case You Missed It: Additional Abstracts of Interest From AACR

Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...

Solid Tumors
Lung Cancer

Effects of Tumor-Infiltrating Clonal Hematopoiesis

In a study reported in The New England Journal of Medicine, Pich et al found that tumor-infiltrating clonal hematopoiesis (TI-CH) was associated with an increased risk of death or recurrence among patients with early-stage non–small cell lung cancer (NSCLC) and poorer overall survival among...

Lung Cancer

Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer

The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed monoclonal antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib in the first-line ...

Solid Tumors
Lung Cancer
Colorectal Cancer
Prostate Cancer
Hematologic Malignancies
Lymphoma
Issues in Oncology

HIV-Related Structural Barriers in Cancer Care

Patients with human immunodeficiency virus (HIV) are less likely to receive potentially life-saving cancer treatment if they reside in communities with lower income levels and educational attainment, according to a recent study published by Islam et al in Cancer. Study Methods and Results...

Lung Cancer

Dose Escalation of Fluorodeoxyglucose PET–Guided Radiotherapy for Locally Advanced NSCLC

In an analysis from the Scandinavian phase III NARLAL2 trial, reported in the Journal of Clinical Oncology, Schytte et al found that fluorodeoxyglucose (FDG)-PET–guided heterogeneously dose-escalated radiotherapy was not associated with greater 6-month toxicity vs standard radiotherapy in...

Lung Cancer

AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer

The novel HER2-targeted tyrosine kinase inhibitor zongertinib elicited durable responses in patients with advanced, previously treated non–small cell lung cancer (NSCLC) that harbored a HER2 mutation, according to the preliminary results of the early-phase Beamion LUNG-1 trial. These findings were...

Lung Cancer
Issues in Oncology
Genomics/Genetics

AACR 2025: Zoldonrasib May Elicit Objective Responses in Patients With KRAS G12D–Mutated NSCLC

The oral KRAS G12D inhibitor zoldonrasib could provide clinical benefit in patients with previously treated non–small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12D mutation, according to new findings presented by Arbour et al at the 2025 American Association for Cancer Research (AACR)...

Supportive Care
Lung Cancer

Managing Dermatologic Reactions to Combination Therapy for Patients With EGFR-Mutated NSCLC

Nicolas Girard, MD, a thoracic oncologist at the Institut Curie, Paris, presented the results of an interim analysis of the open-label phase II COCOON study, at the European Lung Cancer Congress (ELCC) 2025.1 A readily available preventive regimen (the COCOON regimen) reduced moderate-to-severe...

Lung Cancer

Several Trials Show Clinical Activity With Osimertinib in Advanced EGFR-Mutant Non–Small Cell Lung Cancer

Updates from several clinical trials of the EGFR tyrosine kinase inhibitor osimertinib across stages and settings of EGFR-mutated non–small cell lung cancer (NSCLC) were presented at the European Lung Cancer Congress (ELCC) 2025. The updated results from the phase III LAURA trial were presented by ...

Lung Cancer
Leukemia

Therapy With a Tyrosine Kinase Inhibitor for EGFR-Variant Lung Adenocarcinoma: Lessons From Chronic Myeloid Leukemia?

There has been remarkable progress in treating EGFR-variant lung adenocarcinoma with tyrosine kinase inhibitors such as gefitinib, erlotinib, osimertinib, and afatinib. However, several important issues remain unresolved, including whether there remains a role for chemotherapy, who should receive a ...

Lung Cancer
Immunotherapy

Some Patients With Advanced NSCLC Experience Durable Disease Control After Immunotherapy Discontinuation

Although immune checkpoint inhibitors (ICIs) have transformed the treatment landscape over the last decade for patients with non–small cell lung cancer (NSCLC), the agents can also stimulate uncontrolled immunity against normal tissues and organs, leading to a cascade of immune-related adverse...

Lung Cancer

Activity of ROS1 TKI in NSCLC

In a pooled analysis of the phase II TRUST-I and TRUST-II trials reported in the Journal of Clinical Oncology, Pérol et al found that the oral, potent, CNS-active, selective, next-generation ROS1 tyrosine kinase inhibitor (TKI) taletrectinib was highly active in ROS1-positive advanced or metastatic ...

Lung Cancer
Health-Care Policy

How Does Medicaid Expansion Affect Access to Care in Patients With NSCLC?

A recent study published by Hooda et al in The Annals of Thoracic Surgery suggests that Medicaid expansion under the Affordable Care Act has significantly improved access to timely treatment and high-volume hospitals for patients with early-stage non–small cell lung cancer (NSCLC). These findings...

Lung Cancer

Dual Use of Cigarettes and E-Cigarettes on Par With Sole Cigarette Use in Terms of Toxic Exposure

Individuals who reported exclusive use of combustible cigarettes as well as those who reported dual use of both cigarettes and e-cigarettes showed similarly high toxicant exposure, according to the results of a study published in Nicotine & Tobacco Research. Both groups of smokers showed higher ...

CNS Cancers
Skin Cancer
Lung Cancer
Immunotherapy

Immunotherapy, Radiosurgery Combination and Risk of Radiation Necrosis in Patients With Cancer Who Have Brain Metastases

Patients with melanoma and lung cancer who have brain metastases may experience severe inflammatory reactions after receipt of immunotherapy drugs combined with radiation therapy, according to a recent study published by Vaios et al in JAMA Network Open. Study Methods and Results In this study,...

CNS Cancers
Colorectal Cancer
Kidney Cancer
Lung Cancer
Gynecologic Cancers

FDA Approves Bevacizumab Biosimilar

The U.S. Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne), a biosimilar to bevacizumab (Avastin), for intravenous use. Bevacizumab-nwgd is a recombinant humanized monoclonal antibody and a vascular endothelial growth factor (VEGF) inhibitor that binds with VEGF and blocks...

Issues in Oncology
Genomics/Genetics
Solid Tumors
Bladder Cancer
Skin Cancer
Lung Cancer

Novel Strategy May Enhance Sensitivity, Accuracy of Monitoring Cancer in Blood Samples

A whole-genome sequencing–based, error-corrected method for detecting cancer from blood samples could be more sensitive and accurate in monitoring disease status posttreatment among patients with cancer compared with prior methods, according to a recent study published by Cheng et al in Nature...

Breast Cancer
Lung Cancer
Colorectal Cancer

Rates of Breast, CRC Screenings Almost Four Times Higher Than Lung Cancer Screenings

Many patients who are eligible for lung cancer screening do not receive it, but do receive preventative screenings for other cancer types, according to the results of a new study published by Potter et al in JAMA.  Background  Although lung cancer screening is recommended for certain individuals...

Lung Cancer

Patterns in Adherence to USPSTF Lung Cancer Screening Guidelines

In a study reported as a research letter in JAMA Oncology, Rolle et al found increased overall adherence to the 2021 updated U.S. Preventive Services Task Force (USPSTF) lung cancer screening guidelines vs the prior guidelines. In 2021, the USPSTF updated lung cancer screening guidelines by...

Lung Cancer
Issues in Oncology

AI Integration in Global Programs of CT Screening for Lung Cancer and Other Tobacco-Related Illnesses

A new consortium, the Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE), has proposed a public health program of longitudinal chest computed tomography (CT) screenings among a global high-risk population of tobacco-exposed individuals utilizing...

Lung Cancer

Low-Dose CT Screening for Lung Cancer in a High-Risk Population

In a UK prospective longitudinal cohort study (SUMMIT) reported in The Lancet Oncology, Bhamani et al found that large-scale, low-dose computed tomography (CT) screening for lung cancer is effective and “can be delivered efficiently” in a diverse high-risk population. As stated by the...

Lung Cancer
Issues in Oncology

Tobacco Control May Have Prevented Millions of Premature Lung Cancer Deaths in United States

Tobacco control–driven reductions in smoking prevalence may have helped avert over 3.8 million lung cancer–related deaths and gain just over 76 million years of life between 1970 and 2022 in the United States, according to a recent study published by Islami et al in CA: A Cancer Journal for...

lung cancer

Case 3: Unresectable EGFR-Mutant NSCLC

This is Part 3 of EGFR-Mutant NSCLC: Treatment Considerations for Early-Stage Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Stephen Liu, Tina Cascone, and Susan Scott discuss the treatment of unresectable EGFR-mutant non–small cell lung cancer (NSCLC). The patient is a 66-year-old woman with a right upper lobe lung mass found on a screening CT scan. She has a 37-year history of smoking and quit 6 years ago. PET scan showed a hypermetabolic right upper lobe mass and mediastinal adenopathy. Bronchoscopy confirms adenocarcinoma in the right upper lobe and contralateral mediastinal adenopathy in R4, R7, and L4. With biopsy-confirmed N3 adenopathy, the multidisciplinary team determines she has unresectable stage III NSCLC.   In the conversation that follows, the faculty discuss the importance of obtaining molecular testing to ensure optimal management of unresectable NSCLC, the use of concurrent chemoradiation, the role of osimertinib consolidation therapy for patients with EGFR-mutant NSCLC, and their approach to surveillance.

lung cancer

Case 2: Resectable EGFR-Mutant NSCLC

This is Part 2 of EGFR-Mutant NSCLC: Treatment Considerations for Early-Stage Disease, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Stephen Liu, Tina Cascone, and Susan Scott discuss the treatment of resectable EGFR-mutant non–small cell lung cancer (NSCLC). The patient is a 70-year-old man who presented with a persistent cough. Chest x-ray showed a right upper lobe ground glass infiltrate, and symptoms persisted following treatment with antibiotics. A CT scan revealed a suspicious right upper lobe lung nodule, which was hypermetabolic on PET scan with mild uptake in a right paratracheal lymph node. Bronchoscopy and endobronchial ultrasound revealed lung adenocarcinoma in the right upper node and R4 lymph node. He was offered neoadjuvant cisplatin plus pemetrexed plus pembrolizumab, but is seeking another opinion.   In the conversation that follows, the faculty discuss the importance of molecular testing prior to initiating treatment with immunotherapy, how to navigate situations where repeat biopsy is necessary, the role of adjuvant osimertinib following resection for EGFR-mutant NSCLC, and more.

Lung Cancer

Early Research Evaluates Association Between Diet and Lung Cancer Risk

The long-term impact of diet on health has been well studied, leading to guidance about limiting the consumption of red meat, alcohol, and other foods associated with an increased risk of malignancies such as colorectal, breast, and liver cancers. Researchers at the University of Florida Health...

Lung Cancer

Advanced PD-L1–Positive NSCLC: Ivonescimab vs Pembrolizumab

In an interim analysis of a Chinese phase III trial (HARMONi) reported in The Lancet, Xiong et al found that ivonescimab—a bispecific antibody against PD-1 and VEGF—significantly improved progression-free survival vs pembrolizumab in the first-line setting for patients with advanced PD-L1–positive...

Lung Cancer

MRD and Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA NSCLC

The ADAURA trial findings showed a significant benefit in disease-free survival with the EGFR inhibitor osimertinib, compared to placebo, making it the recommended standard of adjuvant treatment in patients with EGFR-mutated non–small cell lung cancer (NSCLC) for up to 3 years after surgery. In a...

Lung Cancer
Issues in Oncology
Genomics/Genetics

Combination Therapy Could Help Overcome Drug Resistance in Patients With KRAS-Mutated NSCLC

Researchers have uncovered a novel combination therapy leveraging the U.S. Food and Drug Administration (FDA)-approved KRAS inhibitor sotorasib and an experimental drug called FGTI-2734, which could improve the efficacy of precision medicine in patients with KRAS-mutated non–small cell lung cancer...

Lung Cancer

Study Finds Wildfires Pose Health Threat for Patients Recovering From Lung Cancer Surgery

Studies have shown that not only does exposure to wildfire smoke, which contains fine particulate matter, increase the risk of developing lung cancer, it can also significantly reduce survival rates among patients recovering from lung cancer surgery. A large national study by researchers at the...

Lung Cancer

Can Plasma ctDNA Kinetics Predict Response to Systemic Therapy in Advanced NSCLC?

In a systematic review and meta-analysis reported in The Oncologist, Leite da Silva et al found plasma circulating tumor DNA (ctDNA) kinetics to be predictive of survival outcomes in patients with advanced non–small cell lung cancer (NSCLC) who were undergoing targeted therapy and immune checkpoint ...

Lung Cancer

Trastuzumab Rezetecan in Advanced HER2-Positive NSCLC

In a Chinese phase II trial (HORIZON-Lung) reported in The Lancet Oncology, Li et al found that trastuzumab rezetecan, a novel antibody-drug conjugate, showed activity in patients with advanced HER2-positive non–small cell lung cancer (NSCLC). Trastuzumab rezetecan consists of a HER2-directed...

Lung Cancer
Supportive Care

Prophylactic Strategy for Preventing Infusion-Related Reactions With IV Amivantamab in EGFR-Mutated NSCLC

Based on results from the phase II SKIPPirr trial, the addition of 8 mg of dexamethasone to standard infusion-related reaction prophylaxis appeared to reduce the incidence of such events by approximately threefold in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC) who were...

Lung Cancer

Final Results of LIBRETTO-001: Selpercatinib in RET Fusion–Positive NSCLC

As reported in the Journal of Clinical Oncology by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York, and colleagues, final results of the registrational phase I/II LIBRETTO-001 trial showed continued benefit of the RET receptor tyrosine...

Lung Cancer
Cardio-oncology
Issues in Oncology

Comprehensive CT Scans May Help to Identify Atherosclerosis Among Patients With Lung Cancer

Several cardiovascular risk factors such as advanced age and smoking history may be prevalent among patients with lung cancer at the time of diagnosis and may increase their risk of future cardiovascular disease, according to findings presented by Malozzi et al at the American College of...

Lung Cancer
Pancreatic Cancer

eNRGy Trial: Zenocutuzumab for NRG1 Gene Fusion–Positive Solid Tumors

Treatment with the HER2 × HER3 bispecific antibody zenocutuzumab-zbco appeared to be safe and active in patients with advanced NRG1 gene fusion–positive solid tumors, according to results from the registrational phase II eNRGy study published by Schram et al in The New England Journal of Medicine....

Palliative Care
Lung Cancer

How Telehealth Is Broadening Access to Early Palliative Care and Improving Outcomes for Patients With Advanced Lung Cancer

Although national guidelines, including ASCO’s palliative care guideline,1 call for the early integration of palliative and oncology care for patients with advanced cancer, only 36% of those with a very poor prognosis and 18% of those with a poor prognosis receive palliative care services.2 The...

Lung Cancer

Mobocertinib vs Platinum-Based Chemotherapy in First-Line Treatment of EGFR Exon 20 Insertion–Positive Metastatic NSCLC

As reported in the Journal of Clinical Oncology by Jänne et al, an interim analysis of the phase III EXCLAIM-2 trial showed no progression-free survival benefit with mobocertinib—an EGFR tyrosine kinase inhibitor (TKI) targeting EGFR exon 20 insertion (ex20ins) mutations—compared with...

Lung Cancer

Lung-MAP 3.0: Simplifying the Process to Meet Patients’ Needs

The Lung Cancer Master Protocol (Lung-MAP) is an innovative clinical trial designed to efficiently address the unmet needs of patients with advanced non–small cell lung cancer (NSCLC) following front-line therapy. This pioneering effort was the first biomarker-driven umbrella master protocol...

Solid Tumors
Issues in Oncology
Breast Cancer
Colorectal Cancer
Gynecologic Cancers
Lung Cancer
Hepatobiliary Cancer

Trends in Cancer Incidence and Mortality in Appalachia

Investigators have found that although fewer patients may be diagnosed with and dying from cancer in Appalachia, cancer incidence and mortality rates remain substantially higher compared with elsewhere in the United States, according to a recent study published by Burus et al in the Journal of the...

Lung Cancer
Genomics/Genetics
Issues in Oncology

Predicting Response to KRAS G12C Inhibitors in NSCLC

Researchers may have uncovered a novel strategy to help predict how well patients with KRAS G12C–mutated non–small cell lung cancer (NSCLC) will respond to new therapies, according to a recent study published by Kato et al in Clinical Cancer Research. Study Methods and Results Researchers developed ...

Lung Cancer

Neoadjuvant Nivolumab/Ipilimumab vs Chemotherapy in Resectable NSCLC

As reported in the Journal of Clinical Oncology by Awad et al, exploratory analysis of the comparison of neoadjuvant nivolumab/ipilimumab vs chemotherapy in the phase III CheckMate 816 trial found that nivolumab/ipilimumab was associated with numerically better event-free survival in patients with...

Lung Cancer
Issues in Oncology

Anatomic Lung Resection May Be Linked to Improved Survival in Early-Stage NSCLC

Anatomic lung resections such as lobectomy and segmentectomy may be associated with improved long-term survival in patients with early-stage non–small cell lung cancer (NSCLC) compared with wedge resection, according to new findings presented at the 2025 Society of Thoracic Surgeons (STS) Annual...

Lung Cancer

Advanced NSCLC With Brain Metastases: Potential Novel Therapeutic Option

In a Chinese phase II study (C-Brain) reported in The Lancet Oncology, Xu et al found that brain radiotherapy in combination with camrelizumab and platinum-doublet chemotherapy produced “promising” results in patients with previously untreated advanced non–small cell lung cancer (NSCLC) with brain...

Lung Cancer

Getting a Lung Cancer Diagnosis Was Shocking

For more than a year before my diagnosis of stage IA non–small cell lung cancer (NSCLC), in 2020, I had been self-treating a relentless chronic cough and a slight feeling of tightness in my chest. The symptoms were similar to asthma, so I began using albuterol inhalers. When they stopped working, I ...

Lung Cancer

Even Low Levels of ctDNA May Be Linked to Recurrence Risk in Early Lung Cancer, Study Finds

Lung cancer is the second most common cancer in the United States, but high recurrence rates persist for patients with early-stage disease. A recent study published by Black et al in Nature Medicine has found that even very low traces of circulating tumor DNA (ctDNA) may be linked to increased...

Issues in Oncology
Lung Cancer

Study Finds Travel Distance to Lung Cancer Screening Facilities Differs by Race and Ethnicity

Lung cancer is the second most common cancer, excluding skin cancer, diagnosed in men and women in the United States. And despite advances in treatment for the disease, which have led to improved survival rates, lung cancer remains the leading cause of cancer mortality in the United States, with...

Lung Cancer
Issues in Oncology
Global Cancer Care

Investigators Have Uncovered Global Trends in Risk Factors Linked to Lung Cancer Mortality

Although lung cancer and related cancer deaths decreased in the world’s 10 most populous countries from 1990 to 2019, these positive statistics may not address trends in mortality linked to tobacco use, air pollution, and asbestos exposure, according to a recent study published by Jani et al in...

Advertisement

Advertisement

Advertisement